

PharmaNutra S.p.A., results come from research.

The PharmaNutra group continues its rapid growth, with double-digit sales increases in the first six months of 2019, thanks to its research and development activities and numerous patents granted.

16th July 2019 – Double-digit growth continues - in terms of units sold, compared to the same period of the previous year - for PharmaNutra S.P.A., Italian pharmaceutical company founded by the brothers Andrea and Roberto Lacorte and leader of the iron-based nutritional supplements sector listed in the AIM Italia market (Aim Italia -Ticker PHN). For the period closed on 30th June 2019, the PharmaNutra group recorded a 12% increase in sales on the Italian market and 11% in its export markets.

These results bear witness to the quality of PharmaNutra products and their popularity on the market, following continuous investments in research and development, which today have generated 6 patents granted with a 20-year term (*including: Iron-based solid composition, expiry 2032; Mineral-based solid composition and mouth-dispersible formulations, expiry 2033; Cetylated fatty acids, expiry 2035*), supported by 91 clinical trials published and 27 studies in progress. Protecting our intellectual property rights, these figures are further strengthened by the 15 unique proprietary functional ingredients.

“This data confirms the many years’ commitment to research and development, as well as the investments made to obtain the patents already granted as well as 8 new patents pending, ensuring that the intellectual property of our products remains protected. These results encourage us to continue with our research, in order to guarantee the highest quality standards on the market, strengthen our leadership position in the nutritional supplements market and further develop our presence in export markets,” stated Roberto Lacorte, **Vice President of PharmaNutra S.p.A.**

PharmaNutra S.p.A.

Founded and led by the President Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra was established in 2003. It develops unique nutritional supplements and innovative nutritional devices, handling the entire production process, from proprietary raw materials to finished product. The efficacy of the products has been demonstrated with a wealth of scientific evidence, with 91 studies published involving more than 6000 subjects. The Group distributes and sells its products in Italy and abroad. In Italy, products are sold through a network of 150 Pharmaceutical Representatives serving doctors and also exclusively selling PharmaNutra products to pharmacies throughout Italy. Products are sold in over 49 countries abroad, through 33 partners selected from among the finest pharmaceutical companies. PharmaNutra leads the market in the production of iron-based nutritional supplements under the SiderAL brand, where it boasts a

number of important patents on sucrosomial technology. Over the years, the Group has developed a precise strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence.

<http://www.PharmaNutra.it>

For Information:

PharmaNutra S.p.A.

Via Delle Lenze, 216/b
56122 Pisa

Tel. +39 050 7846500

Fax +39 050 7846524

investorrelation@PharmaNutra.it

Nomad & Specialist

CFO SIM S.p.A.

Via dell'Annunciata 23/4
20121 Milan

Tel. +39 02 303431

ecm@cfosim.com

Press Office

Spriano Communication&Partners

Tel. +39 02 83635708

Matteo Russo - Cristina Tronconi

Mob. +39 347 9834881 +39 346 0477901

mrusso@sprianocommunication.com

ctronconi@sprianocommunication.com